active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: You are probably right....I'm a little stressed out my mother and sisters are 45 miles outside of New Orleans and I can't find out anything just want a diversion.... Football woulda been nice. There's the weather channel CNN and many more stations covering the weather. JMHO
YEAH they cancelled the showing of Monday night football on ABC... that sucks!
I'm buying Monday!!!
I hope you are right bag8ger..... we have certainly had enough egg in our faces
Form 8-K for DNAPRINT GENOMICS INC
25-Aug-2005
Entry into Material Agreement
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Financial Consulting Agreement with Market Pulse, LLC
On August 19, 2005 the Registrant and Market Pulse, LLC ("Market Pulse") entered into a Financial Consulting Agreement ("Agreement"). Under the Agreement, Market Pulse will develop a program to increase investor awareness of the Registrant, including profiling the Registrant for three months on Market Pulse's website and in its online newsletter sent to subscribers once a week for the next three months. Additionally, Market Pulse has agreed to distribute the Registrant's press releases to its subscribers, and may, in its sole discretion, issue investment opinions based on the press releases.
In exchange for the financial consulting services provided to Registrant, Market Pulse shall receive $75,000 and two million restricted shares of the Registrant's common stock.
Thanks.
Anybody else having problems getting on RB?
Press Release Source: DNAPrint genomics, Inc.
DNAPrint genomics Forensics Technology Featured in USAToday Article Focusing on Growing Use of DNA Testing in Crime Investigations
Thursday August 18, 9:28 am ET
SARASOTA, Fla., Aug. 18, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTC BB:DNAG.OB - News) today announced that the Company's groundbreaking forensics technology for law enforcement was featured in an article about the growing use of DNA testing in crime investigations in yesterday's edition of USAToday newspaper.
ADVERTISEMENT
The feature article on page one and two of the national newspaper focused on advances made by DNAPrint scientists that enable investigators to learn more about potential suspects in criminal investigations. DNAPrint's technology is based on human genome research and is the first to apply empirical methods for the reconstruction of physical appearance from crime scene DNA or human remains. This technology is sold to forensics professionals under the trade name DNAWITNESS(tm) and first gained national attention in 2003 after it led to the apprehension of a serial killer in Louisiana. More recently, DNAWITNESS(tm) assisted investigators in apprehending suspected killers of an unidentified girl dubbed 'Precious Doe,' whose decapitated body was found in Kansas City, Mo. four years ago. Currently, DNAWITNESS(tm) is being used in more than 100 police investigations worldwide.
USAToday quoted Dave Bernard, a Kansas City police detective, as saying DNA ancestry testing ``made a huge difference'' in the Precious Doe case by helping investigators sort through reports about possible suspects. ``It allowed us to prioritize our tips, to give special attention to tips about mixed-race children, for instance. It was invaluable.'' The newspaper went on to say that Bernard and many other police detectives hail the ancestry tests as a breakthrough in crime fighting.
The article noted that conventional DNA tests examine 13 markers (called CODIS markers), while DNAPrint's technology screens 176 markers, thus providing a significant benefit to criminal investigators. The Company's DNAWITNESS(tm) technology can reliably predict a person's genetic ancestry (Indo-European, Sub-Saharan African, East Asian, Native American, or a mixture of those classifications) and certain descriptive information about the person's physical makeup. Individuals showing greater than 50 percent Indo-European are further categorized as Northwest European, Southern European, South East Asian, and Middle Eastern. Additionally, detectives have at their disposal DNAPrint's RETINOME(tm) technology that determines eye color run on the same sample using the same criteria.
DNAPrint's forensic technology has the capability of shifting completely a criminal investigation's focus. For example, in May 2003 the remains of a body were unearthed in a shallow grave near the resort town of Mammoth Lakes, Calif. The remains were sent to the San Francisco Medical Examiner's office, which determined that the victim was a woman, 30 to 40 years old, of Southeast Asian ancestry. The medical examiner's findings were corroborated by eyewitness reports of a short, possibly Asian woman in the area complaining about an abusive spouse or significant other. In August 2004, however, investigators shifted the focus of their investigation after a DNA sample sent to DNAPrint for analysis determined that the victim was 100 percent Native American.
USAToday quoted Paul Dostie, the police detective investigating the Mammoth Lakes case, as saying the DNAPrint's test ``turned around the whole investigation. We're still looking for the killer, but we know a lot more now.''
Commenting on the article, DNAPrint genomics president and chief executive officer Richard Gabriel stated, ``It is clear that our tests, DNAWITNESS(tm), RETINOME(tm), STRWitness, EUROWitness, DNAWitness-Mito, and DNAWitness-Y cover the field in forensics genetics. Detectives, forensic scientists, and medical examiners can use our products and services to corroborate eyewitness reports, help identify human remains, provide descriptions of 'persons of interest' when no witnesses are available and help provide additional genetic ancestry information, as in the 'Precious Doe' case that ultimately led detectives to the suspected killers. We are encouraged by USAToday's coverage and hope that this will spur more detectives and prosecutors to seek our help in solving cases,'' he concluded.
The article can be accessed on USAToday's web site at http://www.usatoday.com/news/nation/2005-08-16-dna_x.htm?POE=click-refer.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(tm), RETINOME(tm) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(tm), and EURO-DNA(tm). Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification tool when other DNA testing either fails to yield results or the sample might be too deteriorated. The Company's first theranostic product (drug/test combination) is PT-401, a 'Super EPO' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
DNAPrint genomics, Inc.
Richard Gabriel
CEO and President
941 366-3400
or
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint genomics, Inc.
Another notable quote...
Bernard and many other police detectives hail the ancestry tests as a breakthrough in crime-fighting.
I like this comment....
DNA ancestry testing "made a huge difference" in the Precious Doe case by helping investigators sort through reports about possible suspects, says Dave Bernard, a Kansas City police detective. "It allowed us to prioritize our tips, to give special attention to tips about mixed-race children, for instance. It was invaluable."
I don't think that's the news he's talking about... IMHO the news he's talking about will be coming from DNAG....???
GREAT FIND thanks for sharing..... should be a PR on this!
0 volume so far.
Welcome back jever00!!!!
10Q out
Way to go Michiko..... I feel good about buying at this level.
Press Release Source: Wolf Greenfield
Personalized Medicine Creates New Patent Opportunities and Dangers, Wolf Greenfield Lawyer Tells Conference
Monday August 15, 10:16 am ET
BOSTON, MA--(MARKET WIRE)--Aug 15, 2005 -- The dawning personalized-medicine revolution will require companies to take new strategies when patenting drugs and diagnostics, Edward R. Gates of Wolf, Greenfield & Sacks, P.C., a Boston intellectual property law firm, told the Drug Discovery Technology & Development World Congress here.
ADVERTISEMENT
"There's going to be a huge opportunity to impact the industry through innovative intellectual-property strategies," said Gates, a senior attorney in the firm's biotechnology practice.
Spurred by the sequencing of the human genome, personal medicine posits that some drugs work for only some people because of genetic differences. For instance, only 30% of the population may have a genetic marker that makes a drug highly effective.
Developing new drugs, companies might be able to run a smaller trial by selecting only patients with the right makeup. This could lead to speedier FDA approval, slash costs and spell the end of the "blockbuster" model for drug development, Gates said.
Makers of existing drugs could benefit even more. Suppose it's learned that a popular drug helps just 60% of the population. The company could file a new patent, make a label change, and possibly win an extra 20 years of exclusivity, he pointed out.
"Anyone Can Infringe"
Patents directed to personalized medicine inventions must be aimed at all the potential infringers, which include chipmakers, software users, pharmacists, diagnostic companies, clinical labs, drug manufacturers, reagent suppliers, distributors and more, he said.
Patenting a personalized drug may not be the primary strategy. "The best protection may be to patent the genetic chip that does the test," Gates said.
International patent law poses complications. Even if a drug is intended for domestic use only, offshoring could complicate matters. For instance, a company might have blood samples analyzed in India. Patent strategies must take this into account.
A potential problem is that case law in Europe precludes patenting some of the types of inventions based on personalized medicine that are patentable here in the US. But diagnostics are patentable there.
"Most pharmaceutical companies aren't involved in diagnostics, which are handled by separate companies. With personalized medicine, that will all change," Gates predicts.
The personalized medicine revolution is in its infancy, and solving IP challenges will likely be a conundrum for some time.
"Crafting solutions will take creativity, taking into account what the FDA requires, what label changes are permitted and who might benefit commercially from the invention," he said.
Wolf Greenfield in Boston (www.wolfgreenfield.com) is one of the most experienced law firms specializing in intellectual property law, including patents, trademarks, copyrights, licensing, trade secrets and related litigation.
Contact:
Contact:
Henry Stimpson
Stimpson Communications
508-647-0705
Email Contact
Sara Crocker
Wolf Greenfield
617-646-8231
Email Contact
Source: Wolf Greenfield
I like, "hold your butts" that's original & hilarious
Good morning ann441j!
Good stuff Arch... I bought more shares of DNAG today.
Thanks ann441j I liked this one...
Study: Forensic DNA underutilized in U.S.
Associated Press
PULLMAN, Wash. - Ophelia McKnight was last seen alive on Jan. 5, 1988, in downtown Seattle. Her body was found a month later. In June, 17 years after the crime, DNA evidence prompted 47-year old Joseph Tice to confess to killing her.
Such outcomes could be much more common, but a new study by researchers at Washington State University finds that forensic DNA analysis is woefully underused in the United States.
The study estimated that 250,000 unsolved rapes and homicides in the United States since 1982 — more than half of such crimes — have yet to be subjected to DNA testing.
"The effectiveness of forensic DNA has created a tremendous testing demand that is not met by the available supply," said Travis Pratt, a criminal justice professor at WSU.
The reasons for low usage include lack of money, trained personnel and other resources for performing the complicated tests. The researchers' survey also found that some law enforcement agencies were reluctant to take and store DNA evidence.
Pratt and his fellow researchers from WSU gathered numbers from 120 crime labs and about 3,400 law enforcement agencies in all 50 states, using a grant from the National Institute of Justice, a government research agency.
They found that some law enforcement agencies still are reluctant to use DNA testing because it is expensive and requires more training, researcher Michael J. Gaffney said.
"We heard from agencies that had never submitted a DNA sample for testing," Gaffney said.
The researchers found that most law enforcement agencies still view DNA evidence as supplemental evidence, more useful to prosecutors in obtaining a conviction than to investigators in identifying the perpetrator.
Many law enforcement agencies were still unaware of the existence of the national DNA database, the study found.
"Nearly one-fourth of all the surveyed law enforcement agencies reported that one of the primary reasons for not sending DNA to a crime laboratory was the lack of a suspect in the case," the study says. "The problem with that is that those are the very types of cases in which the current national DNA database of existing criminal offenders can be most useful."
The report is slated for publication in an upcoming issue of the journal Criminal Justice Policy Review.
The researchers concluded that federal, state and local governments should consider spending more on DNA testing, but did not estimate how much cash will be needed.
A February report by the Bureau of Justice Statistics estimated that 1,900 additional full-time lab workers at a cost of $70 million would be needed across the country to reduce the backlog in forensic laboratories to 30 days for both DNA samples and other crime lab work, which includes fingerprint and fiber analysis and ballistics.
The Bush administration and the states are working to reduce the backlog and are making some progress. Two years ago the Justice Department launched a five-year $1 billion initiative to clear the backlog.
Tice was already in prison on unrelated rape and burglary convictions when DNA evidence implicated him in McKnight's death. Sentencing is set for July 22, and he could spend the next 40 years in prison.
Copyright 2005 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Form 8-K for DNAPRINT GENOMICS INC
10-Aug-2005
Change in Assets
Item 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.
As previously reported on July 8, 2005, the Registrant entered into an agreement to purchase, and simultaneously closed upon the purchase of, securities comprising or convertible into an 18% equity interest in Biofrontera AG ("Biofrontera"), a German company in the pharmaceutical business. The Registrant purchased the interest in Biofrontera from Technologie-Beteiligungs-Gesellschaft mbH ("tbg"), an instrumentality of the German government. The securities purchased were shares of Biofrontera's series A Preferred Stock, as well as certain convertible debt instruments.
On August 4, 2005 the Registrant converted two of the three debt instruments purchased from tbg into 267,299 total shares of Biofrontera common stock. The Registrant paid Biofrontera a subscription price of 1.00 Euro per share in exchange for the issuance of the Biofrontera stock. The Registrant is still waiting to convert the remaining debt instrument into 98,145 shares upon receipt of German government approval. At that time, the Registrant will pay an additional subscription price of 98,145 Euros. Upon conversion of this remaining debt instrument, the Registrant's acquisition of an 18% equity interest in Biofrontera will be complete.
Dead-Cat bounce or turn around?
You gotta admit, "HOLD ON TO YOUR BUTTS" was a classic!
ann441j these guys wouldn't do this, would they?
http://archives.seattletimes.nwsource.com/cgi-bin/texis.cgi/web/vortex/display?slug=hedge07m&dat...
Great find W2P!
People really have a lotta unsettled issues in their minds and hearts, don't they?
Thier minds seem to be focused on the negative side more than the positives.
I'm showing over 500k hits!!!
Arch, that and a couple of patents I thought was our next big announcements.
Unbelievable........
Please don't ask me where.... because I can't find it but I think it was 4 months for some reason
That's funny ann
Ditto loch3... I agree totally with that conclusion of the matter.
Jever think there's news coming?
I feel U ice105.
AMEN loch3.
BBHHAAAAAHAHAHhahaahaaahaha... thanks I needed that!!!
I'm going to shoot Jever
Goodness...... I need a strong drink!